Rheumatoid Arthritis
Conditions
Brief summary
This single arm study will measure the effect of MabThera in combination with methotrexate on the progression of synovitis, the extent of bone marrow edema, and the number of erosions in the wrist and hand of patients with rheumatoid arthritis, using a new MRI technique. Patients will receive MabThera 1000mg i.v. on days 1 and 15, in combination with a stable dosage of 10-25mg/week methotrexate throughout the duration of the study. Further courses of MabThera will be provided to eligible patients. MRI will be performed 1-2 weeks before treatment initiation, and repeated 1 and 6 months after the first MabThera infusion. The anticipated time on study treatment is 1-2 years, and the target sample size is \<100 individuals.
Interventions
1000mg iv on days 1 and 15
10-25mg/week
Sponsors
Study design
Eligibility
Inclusion criteria
* adult patients, 18-75 years of age; * rheumatoid arthritis for \>=3 months and \<=10 years; * inadequate response to methotrexate (12.5-25mg/week) for \>=3 months; * evidence of erosive disease and/or clinical synovitis in a signal joint.
Exclusion criteria
* autoimmune rheumatic diseases other than RA; * surgical operations on bones/joints in 12 weeks prior to baseline visit; * concomitant treatment with biologic agents; * previous treatment with more than one biologic agent approved for RA, or with cell-depleting therapies.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Early Enhancement Rate (REE) | Baseline, Weeks 4 and 24 | A low cost, low field dedicated extremity MRI unit was used, which is specifically designed for the examination of peripheral joints. In addition to the standard OMERACT-RAMRIS scoring system, additional data were elaborated by using dynamic MRI, i.e. Contrast-Enhanced Dynamic MRI (DCE-MRI). This method evaluates the diffusion of the contrast mean in a series of very short sequences thus providing a diffusion curve which is proportionate to the extent of inflammation in the synovial membrane. Numerical parameters used with this method are the slope in the initial phase (rate of early enhancement - REE) and its steady state condition (relative enhancement - RE). REE per second during the first 55 seconds was calculated according to the formula REE55 = (S55-S0)/(S0x55)x100%. The REE shows the slope of the curve of contrast uptake tangential to the α angle and is steeper if inflammation is higher. |
| Relative Enhancement (RE) Score | Baseline, Weeks 4 and 24 | A low cost, low field dedicated extremity MRI unit was used, which is specifically designed for the examination of peripheral joints. In addition to the standard OMERACT-RAMRIS scoring system, additional data were elaborated by using dynamic MRI (DCE-MRI). This method evaluates the diffusion of the contrast mean in a series of very short sequences thus providing a diffusion curve which is proportionate to the extent of inflammation in the synovial membrane. Numerical parameters used with this method are the slope in the initial phase (REE) and its steady state condition (RE). |
| Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) Synovitis Score | Baseline, Week 4, and Week 24 | Extension and degree of synovitis in wrist according to RAMRIS score developed by OMERACT. Synovitis is an area in synovial compartment that shows above normal post-gadolinium enhancement of a thickness greater than width of normal synovium. Synovitis is assessed in 3 wrist regions (distal radioulnar joint; radiocarpal joint; intercarpal and carpometacarpal joints) and in each metacarpophalangeal (MCP) joint. 1st carpometacarpal joint and 1st MCP joint are not scored. Score 0 is normal, and 1-3 (mild, moderate, severe) are by thirds of the presumed maximum volume of enhancing tissue in the synovial compartment. Total synovitis score=the sum of the individual scores (3 wrist regions \[range 0-9\] or 4 MCP joints \[range 0-12\]) for an overall range of 0-21, where 0=no damage and maximum score \[9, 12, or 21\]=most severe damage. Change in synovitis = Follow-up synovitis score - baseline score. |
| OMERACT RAMRIS Bone Edema Score | Baseline, Weeks 4 and 24 | Extension and degree of bone edema in the wrist according to the RAMRIS score developed by OMERACT. Bone edema is a lesion within the trabecular bone, with ill-defined margins and signal characteristics consistent with increased water content. Each bone (wrists: carpal bones, distal radius, distal ulna, metacarpal bases; MCP joints: metacarpal heads, phalangeal bases) is scored separately. The scale of 0-3 was based on the proportion of bone with edema, as follows: 0=no edema; 1=1 percent (%) to 33% of bone was edematous; 2 = 34%-66% of bone was edematous; and 3= 67%-100% of bone was edematous. Total bone edema score=sum of the individual scores for an overall range of 0-69, where 0=no edema and 69=most severe edema. Change in bone edema = follow-up bone edema score - baseline score. |
| OMERACT RAMRIS Erosion Score | Baseline, Week 4, and Week 24 | MRI bone erosion measures a sharply marginated bone lesion, with correct juxta-articular localization and typical signal characteristics, which is visible in 2 planes with a cortical break seen in at least 1 plane. Each bone (wrists: carpal bones, distal radius, distal ulna, metacarpal bases; MCP joints: metacarpal heads, phalangeal bases) scored separately. Scale is 0-10 based on proportion of eroded bone compared to assessed bone volume (0=no erosion; 1=1%-10% of bone eroded; 2=11%-20%, etc). For long bones, assessed bone volume is from articular surface (or best estimated position if absent) to depth of 1 centimeter (cm); in carpal bones it is the whole bone. Total erosion score=sum of individual scores for an overall range of 0-230, where 0=no erosion and 230=most severe erosion. Change in erosion=Follow-up erosion score - baseline score. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Erythrocyte Sedimentation Rate (ESR) | Baseline and Weeks 4, 12, and 24 | ESR was determined using the Westergren method. ESR measures how fast red blood cells (erythrocytes) fall to the bottom of a fine glass tube that is filled with the participant's blood. The higher the sedimentation rate the greater the inflammation. |
| C-Reactive Protein (CRP) | Baseline and Weeks 4, 12, and 24 | CRP measured by milligrams per deciliter (mg/dL). High levels of CRP are indicators of active inflammation. |
| Anti-Cyclic Citrullinated Peptide (Anti-CCP) Autoantibodies Count | Baseline and Weeks 4, 12, and 24 | Anti-CCP autoantibodies count measured by units per milliliter (U/mL). The anti-CCP autoantibodies bind antigenic determinants that contain the unusual amino acid citrulline. The anti-CCP antibody is a highly specific diagnostic test of RA (though with variable sensitivity) and a marker of joint damage with high prognostic significance. |
| Rheumatoid Factor (RF) Immunoglobulin M (IgM) Concentrations | Baseline and Weeks 4, 12, and 24 | RF IgM concentrations measured by international units per milliliter (IU/mL). RF is an antibody reacting against the fragment, crystallizable (Fc) region of IgG. Quantitative measurements have shown a prognostic value in distinguishing between progressive and non-progressive disease in early RA, a correlation with radiologically determined joint damage, and relation with clinical improvement after disease-modifying anti-rheumatic treatment. |
| Total Immunoglobulin (Ig) Concentrations | Baseline and Weeks 4, 12, and 24 | Total Ig concentrations as measured by milligrams per milliliter (mg/mL). |
| Hematocrit Concentration (%) | Baseline and Weeks 4, 12, and 24 | — |
| Percentage of Total B-lymphocytes | Baseline and Weeks 4, 12, and 24 | Concentration of all B-lymphocytes subtypes was assessed. |
| Erosion Score - Right Hand | Baseline and Week 24 | The erosion score per joint of the hands can range from 0 to 5. Erosions were scored 1 if they were discrete but clearly present, and 2 or 3 if they were larger, depending on the surface area of the joint involved. A score of 3 was given if the erosion was large and extended over the imaginary middle of the bone. A score of 5 was given if a complete collapse of the joint was present or if the full surface of the joint was affected. In each joint, individual erosions were summed up to a maximum of 5. The maximal erosion score for each hand was thus 80, considering the 16 areas for erosions per hand. |
| Erosion Score - Left Hand | Baseline and Week 24 | The erosion score per joint of the hands can range from 0 to 5. Erosions were scored 1 if they were discrete but clearly present, and 2 or 3 if they were larger, depending on the surface area of the joint involved. A score of 3 was given if the erosion was large and extended over the imaginary middle of the bone. A score of 5 was given if a complete collapse of the joint was present or if the full surface of the joint was affected. In each joint, individual erosions were summed up to a maximum of 5. The maximal erosion score for each hand was thus 80, considering the 16 areas for erosions per hand. |
| Joint Space Narrowing - Left Hand | Baseline and Week 24 | Joint space narrowing and joint subluxation or luxation are combined in a single score with a range of 0 to 4. A normal joint space was scored 0. A score of 2 was allowed to a focal narrowing of the joint or to a joint space not sufficiently narrowed to be scored 2. The score of 1 was not to be used when the reader was unsure whether there was joint space narrowing. A generalized narrowing leaving more than 50% of the original joint space present was scored 2. A generalized narrowing leaving less than 50% of the original joint space present was scored 3, and a subluxation of a joint was also scored 3. A bony ankylosis or a complete luxation of the joint was scored 4. A total of 13 joints were evaluated for narrowing and the scores were summed (13 x 4 \[maximum per joint\]). Each sum was normalized to a scale of 0 (best possible outcome) to 100 (worst possible outcome). |
| X-Rays: Right Hand Total Score | Baseline and Week 24 | Right hand total scores as measured by X-rays examining erosion and joint space narrowing. Total score was calculated as the sum of the erosion score and the joint space narrowing score and scores ranged from 0 (best possible outcome) to 180 (worst possible outcome). |
| Joint Space Narrowing - Right Hand | Baseline and Week 24 | Joint space narrowing and joint subluxation or luxation are combined in a single score with a range of 0 to 4. A normal joint space was scored 0. A score of 2 was allowed to a focal narrowing of the joint or to a joint space not sufficiently narrowed to be scored 2. The score of 1 was not to be used when the reader was unsure whether there was joint space narrowing. A generalized narrowing leaving more than 50% of the original joint space present was scored 2. A generalized narrowing leaving less than 50% of the original joint space present was scored 3, and a subluxation of a joint was also scored 3. A bony ankylosis or a complete luxation of the joint was scored 4. A total of 13 joints were evaluated for narrowing and the scores were summed (13 times \[x\] 4 \[maximum per joint\]). Each sum was normalized to a scale of 0 (best possible outcome) to 100 (worst possible outcome). |
| X-Rays: Left Hand Total Score | Baseline and Week 24 | Left hand total scores as measured by X-rays examining erosion and joint space narrowing. Total score was calculated as the sum of the erosion score and the joint space narrowing score and ranged from 0 (best possible outcome) to 180 (worst possible outcome). |
| Ritchie Articular Index Scores | Baseline and Weeks 4, 12, and 24 | The Ritchie Articular Index is a graded assessment of tenderness in 26 joint regions. The sum of the grades of tenderness (0=not tender, 1=tender, 2=tender and causes wince, and 3 tender, causes wince and effort to withdraw) elicited by applying firm pressure over the joint margin of articular joints (such as shoulders, elbow, wrists, hips). The scores ranged from 0 (no tenderness) to 78 (most severe tenderness). |
| Health Assessment Questionnaire - Disability Index (HAQ-DI) Score | Baseline and Weeks 4, 12, and 24 | The Stanford HAQ-DI is a participant-reported questionnaire specific for rheumatoid arthritis (RA). It consist of 20 items referring to eight component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Each item within a domain was scored on a 4-point Likert scale from 0 to 3: 0 = no difficulty; 1 = some difficulty; 2 = much difficulty; 3 = unable to do. The highest score reported by the participant for a domain determined the score for that domain. The overall disability index is computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty. |
| Patient's Global Assessment of Pain | Baseline and Weeks 4, 12, and 24 | The participant's assessment of their current level of pain on a 0 to 100 millimeter (mm) horizontal VAS. The left-hand extreme of the line was described as no pain and the right-hand as unbearable pain. The participant was asked to mark the line corresponding to their current level of pain and the distance from the left edge was recorded. |
| DAS28 Score | Baseline and Weeks 4, 12, and 24 | DAS28 calculated from the number of swollen joints and tender joints using the 28-joints count, the erythrocyte sedimentation rate (ESR) (millimeters per hour \[mm/hr\]) and Patient's Global Assessment of Disease Activity (participant-rated arthritis activity assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity. A DAS28 score of less than or equal to (≤) 3.2 = low disease activity, a DAS28 score of \>3.2 to 5.1 = moderate to high disease activity. |
Countries
Italy
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Rituximab + MTX Participants received rituximab 1000 mg IV and methylprednisolone 100 mg IV on Days 1 and 15 and MTX at a stable dose of 10-25 mg/week by mouth or parenterally. Nonresponsive participants (defined as DAS28-CRP score of \>2.6) could have received additional infusions of rituximab 1000 mg (2 infusions, 14 days apart) provided a minimum of 24 weeks had passed since the first infusion of the last course of study medication. | 10 |
| Total | 10 |
Baseline characteristics
| Characteristic | Rituximab + MTX |
|---|---|
| Age, Continuous | 52.42 years STANDARD_DEVIATION 15.681 |
| Sex: Female, Male Female | 6 Participants |
| Sex: Female, Male Male | 4 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 10 / 10 |
| serious Total, serious adverse events | 2 / 10 |
Outcome results
Early Enhancement Rate (REE)
A low cost, low field dedicated extremity MRI unit was used, which is specifically designed for the examination of peripheral joints. In addition to the standard OMERACT-RAMRIS scoring system, additional data were elaborated by using dynamic MRI, i.e. Contrast-Enhanced Dynamic MRI (DCE-MRI). This method evaluates the diffusion of the contrast mean in a series of very short sequences thus providing a diffusion curve which is proportionate to the extent of inflammation in the synovial membrane. Numerical parameters used with this method are the slope in the initial phase (rate of early enhancement - REE) and its steady state condition (relative enhancement - RE). REE per second during the first 55 seconds was calculated according to the formula REE55 = (S55-S0)/(S0x55)x100%. The REE shows the slope of the curve of contrast uptake tangential to the α angle and is steeper if inflammation is higher.
Time frame: Baseline, Weeks 4 and 24
Population: Safety Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Rituximab + MTX | Early Enhancement Rate (REE) | Baseline | 0.356 percent per second | Standard Deviation 0.2651 |
| Rituximab + MTX | Early Enhancement Rate (REE) | Week 4 | 0.489 percent per second | Standard Deviation 0.511 |
| Rituximab + MTX | Early Enhancement Rate (REE) | Change at Week 4 | 0.150 percent per second | Standard Deviation 0.4106 |
| Rituximab + MTX | Early Enhancement Rate (REE) | Week 24 | 0.363 percent per second | Standard Deviation 0.2615 |
| Rituximab + MTX | Early Enhancement Rate (REE) | Change at Week 24 | -0.012 percent per second | Standard Deviation 0.3227 |
OMERACT RAMRIS Bone Edema Score
Extension and degree of bone edema in the wrist according to the RAMRIS score developed by OMERACT. Bone edema is a lesion within the trabecular bone, with ill-defined margins and signal characteristics consistent with increased water content. Each bone (wrists: carpal bones, distal radius, distal ulna, metacarpal bases; MCP joints: metacarpal heads, phalangeal bases) is scored separately. The scale of 0-3 was based on the proportion of bone with edema, as follows: 0=no edema; 1=1 percent (%) to 33% of bone was edematous; 2 = 34%-66% of bone was edematous; and 3= 67%-100% of bone was edematous. Total bone edema score=sum of the individual scores for an overall range of 0-69, where 0=no edema and 69=most severe edema. Change in bone edema = follow-up bone edema score - baseline score.
Time frame: Baseline, Weeks 4 and 24
Population: Safety Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Rituximab + MTX | OMERACT RAMRIS Bone Edema Score | Baseline | 23.2 units on a scale | Standard Deviation 13.56 |
| Rituximab + MTX | OMERACT RAMRIS Bone Edema Score | Week 4 | 23.8 units on a scale | Standard Deviation 15.68 |
| Rituximab + MTX | OMERACT RAMRIS Bone Edema Score | Change at Week 4 | 0.6 units on a scale | Standard Deviation 14.52 |
| Rituximab + MTX | OMERACT RAMRIS Bone Edema Score | Week 24 | 24.0 units on a scale | Standard Deviation 14.66 |
| Rituximab + MTX | OMERACT RAMRIS Bone Edema Score | Change at Week 24 | 0.8 units on a scale | Standard Deviation 16.77 |
OMERACT RAMRIS Erosion Score
MRI bone erosion measures a sharply marginated bone lesion, with correct juxta-articular localization and typical signal characteristics, which is visible in 2 planes with a cortical break seen in at least 1 plane. Each bone (wrists: carpal bones, distal radius, distal ulna, metacarpal bases; MCP joints: metacarpal heads, phalangeal bases) scored separately. Scale is 0-10 based on proportion of eroded bone compared to assessed bone volume (0=no erosion; 1=1%-10% of bone eroded; 2=11%-20%, etc). For long bones, assessed bone volume is from articular surface (or best estimated position if absent) to depth of 1 centimeter (cm); in carpal bones it is the whole bone. Total erosion score=sum of individual scores for an overall range of 0-230, where 0=no erosion and 230=most severe erosion. Change in erosion=Follow-up erosion score - baseline score.
Time frame: Baseline, Week 4, and Week 24
Population: Safety Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Rituximab + MTX | OMERACT RAMRIS Erosion Score | Baseline | 7.9 units on a scale | Standard Deviation 3.67 |
| Rituximab + MTX | OMERACT RAMRIS Erosion Score | Week 4 | 8.1 units on a scale | Standard Deviation 3.63 |
| Rituximab + MTX | OMERACT RAMRIS Erosion Score | Change at Week 4 | 0.2 units on a scale | Standard Deviation 1.14 |
| Rituximab + MTX | OMERACT RAMRIS Erosion Score | Week 24 | 9.1 units on a scale | Standard Deviation 4.38 |
| Rituximab + MTX | OMERACT RAMRIS Erosion Score | Change at Week 24 | 1.2 units on a scale | Standard Deviation 2.39 |
Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) Synovitis Score
Extension and degree of synovitis in wrist according to RAMRIS score developed by OMERACT. Synovitis is an area in synovial compartment that shows above normal post-gadolinium enhancement of a thickness greater than width of normal synovium. Synovitis is assessed in 3 wrist regions (distal radioulnar joint; radiocarpal joint; intercarpal and carpometacarpal joints) and in each metacarpophalangeal (MCP) joint. 1st carpometacarpal joint and 1st MCP joint are not scored. Score 0 is normal, and 1-3 (mild, moderate, severe) are by thirds of the presumed maximum volume of enhancing tissue in the synovial compartment. Total synovitis score=the sum of the individual scores (3 wrist regions \[range 0-9\] or 4 MCP joints \[range 0-12\]) for an overall range of 0-21, where 0=no damage and maximum score \[9, 12, or 21\]=most severe damage. Change in synovitis = Follow-up synovitis score - baseline score.
Time frame: Baseline, Week 4, and Week 24
Population: The Safety Population included all participants who received any portion of the rituximab dose and was used for efficacy and safety analyses.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Rituximab + MTX | Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) Synovitis Score | Baseline | 3.4 units on a scale | Standard Deviation 1.58 |
| Rituximab + MTX | Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) Synovitis Score | Week 4 | 2.3 units on a scale | Standard Deviation 2.75 |
| Rituximab + MTX | Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) Synovitis Score | Change at Week 4 | -1.1 units on a scale | Standard Deviation 2.38 |
| Rituximab + MTX | Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) Synovitis Score | Week 24 | 2.4 units on a scale | Standard Deviation 1.74 |
| Rituximab + MTX | Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) Synovitis Score | Change at Week 24 | -1.0 units on a scale | Standard Deviation 1.73 |
Relative Enhancement (RE) Score
A low cost, low field dedicated extremity MRI unit was used, which is specifically designed for the examination of peripheral joints. In addition to the standard OMERACT-RAMRIS scoring system, additional data were elaborated by using dynamic MRI (DCE-MRI). This method evaluates the diffusion of the contrast mean in a series of very short sequences thus providing a diffusion curve which is proportionate to the extent of inflammation in the synovial membrane. Numerical parameters used with this method are the slope in the initial phase (REE) and its steady state condition (RE).
Time frame: Baseline, Weeks 4 and 24
Population: Safety Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Rituximab + MTX | Relative Enhancement (RE) Score | Baseline | 66.978 percent | Standard Deviation 42.3981 |
| Rituximab + MTX | Relative Enhancement (RE) Score | Week 4 | 57.889 percent | Standard Deviation 51.9276 |
| Rituximab + MTX | Relative Enhancement (RE) Score | Change at Week 4 | -3.812 percent | Standard Deviation 34.3034 |
| Rituximab + MTX | Relative Enhancement (RE) Score | Week 24 | 40.075 percent | Standard Deviation 21.6891 |
| Rituximab + MTX | Relative Enhancement (RE) Score | Change at Week 24 | -34.450 percent | Standard Deviation 32.9609 |
Anti-Cyclic Citrullinated Peptide (Anti-CCP) Autoantibodies Count
Anti-CCP autoantibodies count measured by units per milliliter (U/mL). The anti-CCP autoantibodies bind antigenic determinants that contain the unusual amino acid citrulline. The anti-CCP antibody is a highly specific diagnostic test of RA (though with variable sensitivity) and a marker of joint damage with high prognostic significance.
Time frame: Baseline and Weeks 4, 12, and 24
Population: Safety Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Rituximab + MTX | Anti-Cyclic Citrullinated Peptide (Anti-CCP) Autoantibodies Count | Baseline | 55.230 U/mL | Standard Deviation 33.3902 |
| Rituximab + MTX | Anti-Cyclic Citrullinated Peptide (Anti-CCP) Autoantibodies Count | Week 4 | 44.311 U/mL | Standard Deviation 28.4448 |
| Rituximab + MTX | Anti-Cyclic Citrullinated Peptide (Anti-CCP) Autoantibodies Count | Change at Week 4 | -10.133 U/mL | Standard Deviation 18.0815 |
| Rituximab + MTX | Anti-Cyclic Citrullinated Peptide (Anti-CCP) Autoantibodies Count | Week 12 | 41.925 U/mL | Standard Deviation 32.2708 |
| Rituximab + MTX | Anti-Cyclic Citrullinated Peptide (Anti-CCP) Autoantibodies Count | Change at Week 12 | -12.862 U/mL | Standard Deviation 16.7306 |
| Rituximab + MTX | Anti-Cyclic Citrullinated Peptide (Anti-CCP) Autoantibodies Count | Week 24 | 122.230 U/mL | Standard Deviation 247.7763 |
| Rituximab + MTX | Anti-Cyclic Citrullinated Peptide (Anti-CCP) Autoantibodies Count | Change at Week 24 | 67.000 U/mL | Standard Deviation 247.0019 |
C-Reactive Protein (CRP)
CRP measured by milligrams per deciliter (mg/dL). High levels of CRP are indicators of active inflammation.
Time frame: Baseline and Weeks 4, 12, and 24
Population: Safety Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Rituximab + MTX | C-Reactive Protein (CRP) | Baseline | 21.630 mg/dL | Standard Deviation 24.1805 |
| Rituximab + MTX | C-Reactive Protein (CRP) | Week 4 | 23.480 mg/dL | Standard Deviation 22.7518 |
| Rituximab + MTX | C-Reactive Protein (CRP) | Change at Week 4 | 1.850 mg/dL | Standard Deviation 16.9261 |
| Rituximab + MTX | C-Reactive Protein (CRP) | Week 12 | 10.929 mg/dL | Standard Deviation 12.2432 |
| Rituximab + MTX | C-Reactive Protein (CRP) | Change at Week 12 | -10.929 mg/dL | Standard Deviation 18.1919 |
| Rituximab + MTX | C-Reactive Protein (CRP) | Week 24 | 23.410 mg/dL | Standard Deviation 26.8998 |
| Rituximab + MTX | C-Reactive Protein (CRP) | Change at Week 24 | 1.780 mg/dL | Standard Deviation 36.7504 |
DAS28 Score
DAS28 calculated from the number of swollen joints and tender joints using the 28-joints count, the erythrocyte sedimentation rate (ESR) (millimeters per hour \[mm/hr\]) and Patient's Global Assessment of Disease Activity (participant-rated arthritis activity assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity. A DAS28 score of less than or equal to (≤) 3.2 = low disease activity, a DAS28 score of \>3.2 to 5.1 = moderate to high disease activity.
Time frame: Baseline and Weeks 4, 12, and 24
Population: Safety Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Rituximab + MTX | DAS28 Score | Baseline | 5.735 units on a scale | Standard Deviation 0.8099 |
| Rituximab + MTX | DAS28 Score | Week 4 | 5.261 units on a scale | Standard Deviation 1.5552 |
| Rituximab + MTX | DAS28 Score | Change at Week 4 | -0.474 units on a scale | Standard Deviation 0.925 |
| Rituximab + MTX | DAS28 Score | Week 12 | 4.307 units on a scale | Standard Deviation 1.4552 |
| Rituximab + MTX | DAS28 Score | Change at Week 12 | -1.587 units on a scale | Standard Deviation 0.9743 |
| Rituximab + MTX | DAS28 Score | Week 24 | 4.400 units on a scale | Standard Deviation 1.4263 |
| Rituximab + MTX | DAS28 Score | Change at Week 24 | -1.335 units on a scale | Standard Deviation 1.1425 |
Erosion Score - Left Hand
The erosion score per joint of the hands can range from 0 to 5. Erosions were scored 1 if they were discrete but clearly present, and 2 or 3 if they were larger, depending on the surface area of the joint involved. A score of 3 was given if the erosion was large and extended over the imaginary middle of the bone. A score of 5 was given if a complete collapse of the joint was present or if the full surface of the joint was affected. In each joint, individual erosions were summed up to a maximum of 5. The maximal erosion score for each hand was thus 80, considering the 16 areas for erosions per hand.
Time frame: Baseline and Week 24
Population: Safety Population; n=number of participants with values for analysis at the specified timepoints.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Rituximab + MTX | Erosion Score - Left Hand | Baseline (n=10) | 1.90 units on a scale | Standard Deviation 2.558 |
| Rituximab + MTX | Erosion Score - Left Hand | Week 24 (n=8) | 1.75 units on a scale | Standard Deviation 2.619 |
| Rituximab + MTX | Erosion Score - Left Hand | Change at Week 24 (n=8) | 0.00 units on a scale | Standard Deviation 0.707 |
Erosion Score - Right Hand
The erosion score per joint of the hands can range from 0 to 5. Erosions were scored 1 if they were discrete but clearly present, and 2 or 3 if they were larger, depending on the surface area of the joint involved. A score of 3 was given if the erosion was large and extended over the imaginary middle of the bone. A score of 5 was given if a complete collapse of the joint was present or if the full surface of the joint was affected. In each joint, individual erosions were summed up to a maximum of 5. The maximal erosion score for each hand was thus 80, considering the 16 areas for erosions per hand.
Time frame: Baseline and Week 24
Population: Safety Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Rituximab + MTX | Erosion Score - Right Hand | Baseline | 2.50 units on a scale | Standard Deviation 2.972 |
| Rituximab + MTX | Erosion Score - Right Hand | Week 24 | 2.19 units on a scale | Standard Deviation 2.963 |
| Rituximab + MTX | Erosion Score - Right Hand | Change at Week 24 | -0.44 units on a scale | Standard Deviation 1.741 |
Erythrocyte Sedimentation Rate (ESR)
ESR was determined using the Westergren method. ESR measures how fast red blood cells (erythrocytes) fall to the bottom of a fine glass tube that is filled with the participant's blood. The higher the sedimentation rate the greater the inflammation.
Time frame: Baseline and Weeks 4, 12, and 24
Population: Safety Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Rituximab + MTX | Erythrocyte Sedimentation Rate (ESR) | Baseline | 72.6 mm/hr | Standard Deviation 27.56 |
| Rituximab + MTX | Erythrocyte Sedimentation Rate (ESR) | Week 4 | 63.8 mm/hr | Standard Deviation 26.63 |
| Rituximab + MTX | Erythrocyte Sedimentation Rate (ESR) | Change at Week 4 | -15.6 mm/hr | Standard Deviation 15.61 |
| Rituximab + MTX | Erythrocyte Sedimentation Rate (ESR) | Week 12 | 48.0 mm/hr | Standard Deviation 26.12 |
| Rituximab + MTX | Erythrocyte Sedimentation Rate (ESR) | Change at Week 12 | -30.2 mm/hr | Standard Deviation 26.47 |
| Rituximab + MTX | Erythrocyte Sedimentation Rate (ESR) | Week 24 | 53.4 mm/hr | Standard Deviation 18.34 |
| Rituximab + MTX | Erythrocyte Sedimentation Rate (ESR) | Change at Week 24 | -19.1 mm/hr | Standard Deviation 21.25 |
Health Assessment Questionnaire - Disability Index (HAQ-DI) Score
The Stanford HAQ-DI is a participant-reported questionnaire specific for rheumatoid arthritis (RA). It consist of 20 items referring to eight component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Each item within a domain was scored on a 4-point Likert scale from 0 to 3: 0 = no difficulty; 1 = some difficulty; 2 = much difficulty; 3 = unable to do. The highest score reported by the participant for a domain determined the score for that domain. The overall disability index is computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.
Time frame: Baseline and Weeks 4, 12, and 24
Population: Safety Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Rituximab + MTX | Health Assessment Questionnaire - Disability Index (HAQ-DI) Score | Baseline | 1.788 units on a scale | Standard Deviation 0.6848 |
| Rituximab + MTX | Health Assessment Questionnaire - Disability Index (HAQ-DI) Score | Week 4 | 1.471 units on a scale | Standard Deviation 0.7976 |
| Rituximab + MTX | Health Assessment Questionnaire - Disability Index (HAQ-DI) Score | Change at Week 4 | -0.316 units on a scale | Standard Deviation 0.3687 |
| Rituximab + MTX | Health Assessment Questionnaire - Disability Index (HAQ-DI) Score | Week 12 | 0.838 units on a scale | Standard Deviation 0.6668 |
| Rituximab + MTX | Health Assessment Questionnaire - Disability Index (HAQ-DI) Score | Change at Week 12 | -0.950 units on a scale | Standard Deviation 0.7997 |
| Rituximab + MTX | Health Assessment Questionnaire - Disability Index (HAQ-DI) Score | Week 24 | 0.888 units on a scale | Standard Deviation 0.7008 |
| Rituximab + MTX | Health Assessment Questionnaire - Disability Index (HAQ-DI) Score | Change at Week 24 | -0.900 units on a scale | Standard Deviation 0.6503 |
Hematocrit Concentration (%)
Time frame: Baseline and Weeks 4, 12, and 24
Population: Safety Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Rituximab + MTX | Hematocrit Concentration (%) | Baseline | 36.110 percentage | Standard Deviation 2.2218 |
| Rituximab + MTX | Hematocrit Concentration (%) | Week 4 | 37.860 percentage | Standard Deviation 1.4315 |
| Rituximab + MTX | Hematocrit Concentration (%) | Change at Week 4 | 1.750 percentage | Standard Deviation 2.9497 |
| Rituximab + MTX | Hematocrit Concentration (%) | Week 12 | 37.512 percentage | Standard Deviation 2.5798 |
| Rituximab + MTX | Hematocrit Concentration (%) | Change at Week 12 | 1.350 percentage | Standard Deviation 4.3065 |
| Rituximab + MTX | Hematocrit Concentration (%) | Week 24 | 37.967 percentage | Standard Deviation 2.6106 |
| Rituximab + MTX | Hematocrit Concentration (%) | Change at Week 24 | 1.667 percentage | Standard Deviation 3.6695 |
Joint Space Narrowing - Left Hand
Joint space narrowing and joint subluxation or luxation are combined in a single score with a range of 0 to 4. A normal joint space was scored 0. A score of 2 was allowed to a focal narrowing of the joint or to a joint space not sufficiently narrowed to be scored 2. The score of 1 was not to be used when the reader was unsure whether there was joint space narrowing. A generalized narrowing leaving more than 50% of the original joint space present was scored 2. A generalized narrowing leaving less than 50% of the original joint space present was scored 3, and a subluxation of a joint was also scored 3. A bony ankylosis or a complete luxation of the joint was scored 4. A total of 13 joints were evaluated for narrowing and the scores were summed (13 x 4 \[maximum per joint\]). Each sum was normalized to a scale of 0 (best possible outcome) to 100 (worst possible outcome).
Time frame: Baseline and Week 24
Population: Safety Population; only participants with values at both Baseline and Week 24 were included in the analysis.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Rituximab + MTX | Joint Space Narrowing - Left Hand | Baseline | 8.45 units on a scale | Standard Deviation 6.039 |
| Rituximab + MTX | Joint Space Narrowing - Left Hand | Week 24 | 9.13 units on a scale | Standard Deviation 6.004 |
| Rituximab + MTX | Joint Space Narrowing - Left Hand | Change at Week 24 | 2.19 units on a scale | Standard Deviation 5.694 |
Joint Space Narrowing - Right Hand
Joint space narrowing and joint subluxation or luxation are combined in a single score with a range of 0 to 4. A normal joint space was scored 0. A score of 2 was allowed to a focal narrowing of the joint or to a joint space not sufficiently narrowed to be scored 2. The score of 1 was not to be used when the reader was unsure whether there was joint space narrowing. A generalized narrowing leaving more than 50% of the original joint space present was scored 2. A generalized narrowing leaving less than 50% of the original joint space present was scored 3, and a subluxation of a joint was also scored 3. A bony ankylosis or a complete luxation of the joint was scored 4. A total of 13 joints were evaluated for narrowing and the scores were summed (13 times \[x\] 4 \[maximum per joint\]). Each sum was normalized to a scale of 0 (best possible outcome) to 100 (worst possible outcome).
Time frame: Baseline and Week 24
Population: Safety Population; only participants with values at both Baseline and Week 24 were included in the analysis.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Rituximab + MTX | Joint Space Narrowing - Right Hand | Baseline | 10.40 units on a scale | Standard Deviation 7.859 |
| Rituximab + MTX | Joint Space Narrowing - Right Hand | Week 24 | 10.13 units on a scale | Standard Deviation 6.786 |
| Rituximab + MTX | Joint Space Narrowing - Right Hand | Change at Week 24 | 0.94 units on a scale | Standard Deviation 6.609 |
Patient's Global Assessment of Pain
The participant's assessment of their current level of pain on a 0 to 100 millimeter (mm) horizontal VAS. The left-hand extreme of the line was described as no pain and the right-hand as unbearable pain. The participant was asked to mark the line corresponding to their current level of pain and the distance from the left edge was recorded.
Time frame: Baseline and Weeks 4, 12, and 24
Population: Safety Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Rituximab + MTX | Patient's Global Assessment of Pain | Baseline | 60.6 mm | Standard Deviation 22.75 |
| Rituximab + MTX | Patient's Global Assessment of Pain | Week 4 | 49.0 mm | Standard Deviation 31.73 |
| Rituximab + MTX | Patient's Global Assessment of Pain | Change at Week 4 | -11.6 mm | Standard Deviation 20.38 |
| Rituximab + MTX | Patient's Global Assessment of Pain | Week 12 | 34.7 mm | Standard Deviation 16.77 |
| Rituximab + MTX | Patient's Global Assessment of Pain | Change at Week 12 | -29.9 mm | Standard Deviation 28.27 |
| Rituximab + MTX | Patient's Global Assessment of Pain | Week 24 | 22.7 mm | Standard Deviation 16.92 |
| Rituximab + MTX | Patient's Global Assessment of Pain | Change at Week 24 | -30.7 mm | Standard Deviation 23.69 |
Percentage of Total B-lymphocytes
Concentration of all B-lymphocytes subtypes was assessed.
Time frame: Baseline and Weeks 4, 12, and 24
Population: Safety Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Rituximab + MTX | Percentage of Total B-lymphocytes | Baseline | 24.040 percentage of cells | Standard Deviation 10.2954 |
| Rituximab + MTX | Percentage of Total B-lymphocytes | Week 4 | 22.430 percentage of cells | Standard Deviation 8.0601 |
| Rituximab + MTX | Percentage of Total B-lymphocytes | Change at Week 4 | -1.610 percentage of cells | Standard Deviation 7.1818 |
| Rituximab + MTX | Percentage of Total B-lymphocytes | Week 12 | 30.125 percentage of cells | Standard Deviation 12.0576 |
| Rituximab + MTX | Percentage of Total B-lymphocytes | Change at Week 12 | 5.562 percentage of cells | Standard Deviation 11.6748 |
| Rituximab + MTX | Percentage of Total B-lymphocytes | Week 24 | 24.133 percentage of cells | Standard Deviation 10.2802 |
| Rituximab + MTX | Percentage of Total B-lymphocytes | Change at Week 24 | 1.111 percentage of cells | Standard Deviation 7.7194 |
Rheumatoid Factor (RF) Immunoglobulin M (IgM) Concentrations
RF IgM concentrations measured by international units per milliliter (IU/mL). RF is an antibody reacting against the fragment, crystallizable (Fc) region of IgG. Quantitative measurements have shown a prognostic value in distinguishing between progressive and non-progressive disease in early RA, a correlation with radiologically determined joint damage, and relation with clinical improvement after disease-modifying anti-rheumatic treatment.
Time frame: Baseline and Weeks 4, 12, and 24
Population: Safety Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Rituximab + MTX | Rheumatoid Factor (RF) Immunoglobulin M (IgM) Concentrations | Baseline | 570.922 IU/mL | Standard Deviation 827.09 |
| Rituximab + MTX | Rheumatoid Factor (RF) Immunoglobulin M (IgM) Concentrations | Week 4 | 307.300 IU/mL | Standard Deviation 337.955 |
| Rituximab + MTX | Rheumatoid Factor (RF) Immunoglobulin M (IgM) Concentrations | Change at Week 4 | -285.138 IU/mL | Standard Deviation 530.8209 |
| Rituximab + MTX | Rheumatoid Factor (RF) Immunoglobulin M (IgM) Concentrations | Week 12 | 241.756 IU/mL | Standard Deviation 357.8067 |
| Rituximab + MTX | Rheumatoid Factor (RF) Immunoglobulin M (IgM) Concentrations | Change at Week 12 | -329.167 IU/mL | Standard Deviation 499.0426 |
| Rituximab + MTX | Rheumatoid Factor (RF) Immunoglobulin M (IgM) Concentrations | Week 24 | 281.230 IU/mL | Standard Deviation 337.6633 |
| Rituximab + MTX | Rheumatoid Factor (RF) Immunoglobulin M (IgM) Concentrations | Change at Week 24 | -267.389 IU/mL | Standard Deviation 529.7928 |
Ritchie Articular Index Scores
The Ritchie Articular Index is a graded assessment of tenderness in 26 joint regions. The sum of the grades of tenderness (0=not tender, 1=tender, 2=tender and causes wince, and 3 tender, causes wince and effort to withdraw) elicited by applying firm pressure over the joint margin of articular joints (such as shoulders, elbow, wrists, hips). The scores ranged from 0 (no tenderness) to 78 (most severe tenderness).
Time frame: Baseline and Weeks 4, 12, and 24
Population: Safety Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Rituximab + MTX | Ritchie Articular Index Scores | Change at Week 12 | -11.2 units on a scale | Standard Deviation 6.11 |
| Rituximab + MTX | Ritchie Articular Index Scores | Baseline | 20.7 units on a scale | Standard Deviation 8.3 |
| Rituximab + MTX | Ritchie Articular Index Scores | Week 4 | 16.9 units on a scale | Standard Deviation 9.49 |
| Rituximab + MTX | Ritchie Articular Index Scores | Change at Week 4 | -3.8 units on a scale | Standard Deviation 6.78 |
| Rituximab + MTX | Ritchie Articular Index Scores | Week 12 | 9.5 units on a scale | Standard Deviation 6.72 |
| Rituximab + MTX | Ritchie Articular Index Scores | Week 24 | 11.7 units on a scale | Standard Deviation 9.6 |
| Rituximab + MTX | Ritchie Articular Index Scores | Change at Week 24 | -9.0 units on a scale | Standard Deviation 6.5 |
Total Immunoglobulin (Ig) Concentrations
Total Ig concentrations as measured by milligrams per milliliter (mg/mL).
Time frame: Baseline and Weeks 4, 12, and 24
Population: Safety Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Rituximab + MTX | Total Immunoglobulin (Ig) Concentrations | Baseline | 20.258 mg/mL | Standard Deviation 6.7055 |
| Rituximab + MTX | Total Immunoglobulin (Ig) Concentrations | Week 4 | 17.786 mg/mL | Standard Deviation 4.7033 |
| Rituximab + MTX | Total Immunoglobulin (Ig) Concentrations | Change at Week 4 | -1.602 mg/mL | Standard Deviation 3.6846 |
| Rituximab + MTX | Total Immunoglobulin (Ig) Concentrations | Week 12 | 17.296 mg/mL | Standard Deviation 4.1845 |
| Rituximab + MTX | Total Immunoglobulin (Ig) Concentrations | Change at Week 12 | -2.336 mg/mL | Standard Deviation 4.0998 |
| Rituximab + MTX | Total Immunoglobulin (Ig) Concentrations | Week 24 | 18.354 mg/mL | Standard Deviation 4.3432 |
| Rituximab + MTX | Total Immunoglobulin (Ig) Concentrations | Change at Week 24 | -1.042 mg/mL | Standard Deviation 4.5527 |
X-Rays: Left Hand Total Score
Left hand total scores as measured by X-rays examining erosion and joint space narrowing. Total score was calculated as the sum of the erosion score and the joint space narrowing score and ranged from 0 (best possible outcome) to 180 (worst possible outcome).
Time frame: Baseline and Week 24
Population: Safety Population; only participants with values at both Baseline and Week 24 were included in the analysis.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Rituximab + MTX | X-Rays: Left Hand Total Score | Baseline | 10.35 units on a scale | Standard Deviation 7.192 |
| Rituximab + MTX | X-Rays: Left Hand Total Score | Week 24 | 10.88 units on a scale | Standard Deviation 6.813 |
| Rituximab + MTX | X-Rays: Left Hand Total Score | Change at Week 24 | 2.19 units on a scale | Standard Deviation 6.341 |
X-Rays: Right Hand Total Score
Right hand total scores as measured by X-rays examining erosion and joint space narrowing. Total score was calculated as the sum of the erosion score and the joint space narrowing score and scores ranged from 0 (best possible outcome) to 180 (worst possible outcome).
Time frame: Baseline and Week 24
Population: Safety Population; only participants with values at both Baseline and Week 24 were included in the analysis.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Rituximab + MTX | X-Rays: Right Hand Total Score | Baseline | 12.90 units on a scale | Standard Deviation 9.433 |
| Rituximab + MTX | X-Rays: Right Hand Total Score | Week 24 | 12.31 units on a scale | Standard Deviation 7.828 |
| Rituximab + MTX | X-Rays: Right Hand Total Score | Change at Week 24 | 0.50 units on a scale | Standard Deviation 7.714 |